ArticleBMC medical imaging2026
Construction of novel radiomics nomogram model based on preoperative CT to predict lymphovascular tumor embolus and recurrence-free survival in early T1-2a stage lung adenocarcinomas.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo construct a radiomics nomogram model predicting the status of lymphovascular tumor embolus (LTE) in patients with lung invasive adenocarcinoma (LAC). MATERIALS AND
methodsThis retrospective analysis enrolled 195 patients with pathologically-confirmed LAC, treated at Weifang People's Hospital between January 2018 and April 2021, including 152 and 43 cases in the LTE and non-LTE groups, respectively. Regions of interest were manually delineated on preoperative CT images using 3D slicer. Subsequently, 850 radiomics features were extracted and subjected to feature reduction through least absolute shrinkage and selection operator regression. The effectiveness of the predictive model was evaluated using receiver operating characteristic curves, calibration, and decision curve analysis. The log-rank test was applied to data split into low-score and high-score groups to analyze early recurrence-free survival based on the optimal cutoff value established in the mixed model.
resultsFive identified feature parameters were applied to establish a rad-score. Hybrid prediction model integrating smoking status and radiomics signature demonstrated better predictive efficacy than the radiomics models in the training cohort (area under the curve [AUC], 0.9210 vs. 0.8781) and validation cohort (AUC, 0.8807 vs. 0.8770), although without reaching statistical significance. The calibration curves of the nomogram illustrated the goodness-of-fit to predict LTE status in both cohorts. Kaplan-Meier survival curve analysis demonstrated a significant difference in recurrence-free survival rate between the low-score and high-score groups, as predicted based on the optimal cutoff value of the mixed model.
conclusionCT radiomics-based model, which could serve as a potential biomarker, demonstrated strong predictive value for LTE status in LAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.